Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,774 across all filing types
Latest filing 2017-11-08 Earnings Release
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
EVOTEC AG ANNOUNCES FIRST NINE-MONTH 2017 RESULTS AND CORPORATE UPDATE
Earnings Release Classification · 100% confidence The document is titled "EVOTEC AG ANNOUNCES FIRST NINE-MONTH 2017 RESULTS AND CORPORATE UPDATE" and explicitly details financial performance metrics for the 'first nine months of 2017' (9M 2017). This content structure—comprehensive financial review for a period shorter than a year—is characteristic of an Interim/Quarterly Report. Although it announces a conference call (suggesting CT or ER), the core content is the detailed financial breakdown, making it an Interim Report (IR) rather than just an Earnings Release (ER) which typically contains only highlights. It is not a full Annual Report (10-K). 9M 2017
2017-11-08 English
Präsentation Q3 2017
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Statement First Nine Months 2017' and contains detailed financial statements, including income statements and balance sheets for the 9M 2017 period. It provides a comprehensive analysis of business performance, segment information, and financial trends. As it contains substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2017
2017-11-08 English
Q3 statement / Q3 financial report 2017
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Statement First Nine Months 2017' and contains detailed financial statements, including income statements and balance sheets for the 9M 2017 period. It provides a comprehensive analysis of business performance, segment information, and financial trends. As it contains substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2017
2017-11-08 German
EVOTEC JOINS FORCES WITH ACADEMIC LEADERS TO ACCELERATE DRUG DISCOVERY IN KIDNEY DISEASES AND BUILD 'NEPLEX'
Regulatory Filings Classification · 100% confidence The document is a press release dated November 6, 2017, announcing a strategic collaboration between Evotec AG and several academic institutions to accelerate drug discovery in kidney diseases. It uses the header 'DGAP-News' and discusses a new project ('NEPLEX'). This type of announcement, detailing a significant business development (a new alliance/partnership) that is not a formal financial report (like 10-K or IR), earnings release (ER), or a capital change (CAP), typically falls under general corporate news or regulatory announcements. Since it is a specific announcement about a strategic alliance, it is best classified as a Regulatory Filing (RNS) as it is a general corporate news item disseminated via a service like DGAP, which serves as a fallback for non-standard filings, or potentially a general announcement that doesn't fit the highly specific categories like M&A (TAR) or Financing (CAP). Given the context of corporate news dissemination via DGAP, RNS is the most appropriate general category for this type of material that isn't a core financial report or management change.
2017-11-06 English
EVOTEC AG TO REPORT FIRST NINE-MONTH 2017 RESULTS ON 08 NOVEMBER 2017
Report Publication Announcement Classification · 99% confidence The document is a news release dated November 2, 2017, announcing that EVOTEC AG will report its financial results for the first nine months of 2017 on November 8, 2017. It explicitly details the date, time, and dial-in information for the subsequent conference call to discuss these results. This is not the actual financial report (which would be an IR or ER), but rather an announcement about the upcoming release of results and the associated call. According to Rule 2, if a document announces the publication of a report and provides details for a related event (like a conference call), it fits the description of a Report Publication Announcement (RPA). It is not a general regulatory filing (RNS) because it is specific to a scheduled financial event.
2017-11-02 English
Evotec AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a short announcement (1555 chars) titled 'Total Voting Rights Announcement' from Evotec AG, referencing Article 26a of the WpHG (German Securities Trading Act). It explicitly states the 'Publication of total number of voting rights' and details a 'Conditional capital increase' effective on 30.10.2017, resulting in a new total of 147,516,272 voting rights. This type of announcement, which reports a change in the total number of shares/voting rights, fits best under 'Share Issue/Capital Change' (SHA) as it relates directly to the capital structure, even though it is framed as a regulatory disclosure via DGAP. It is not a full report (10-K, IR), nor is it a general dividend notice (DIV) or insider trade (DIRS). Since it details a capital measure (conditional capital increase), SHA is the most specific fit.
2017-10-30 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.